Prosecution Insights
Last updated: October 27, 2026
Application No. 18/576,970

STERICALLY MODIFIED SCHIFF BASE LIGANDS FOR ENHANCED CATALYTIC CARBONYLATION ACTIVITY

Non-Final OA §103
Filed
Jan 05, 2024
Priority
Jul 09, 2021 — provisional 63/220,126 +1 more
Examiner
BAUER, NICOLA MARIA
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novomer LLC
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
37 granted / 63 resolved
-1.3% vs TC avg
Strong +52% interview lift
Without
With
+52.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
37 currently pending
Career history
102
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
48.8%
+8.8% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
13.9%
-26.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-6, 9, 13, 18-25, 27-28, and 30-31 are pending. Claims 18-25, 27-28, and 30-31 are withdrawn. Priority Applicant’s claim for benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. This application is a national stage entry of and claims priority to PCT/US2022/073501 filed on 7/7/2022 and further claims priority to PRO application number 63/220,126, filed 7/09/2021. Information Disclosure Statement All references from IDS(s) received on 2/12/2024 have been considered unless marked with a strikethrough. Elections/Restrictions Applicant’s election of Group I with traverse in the reply filed on 7/29/2026 is acknowledged. Applicant’s election of M: aluminum, R3: o-phenylenediamine, PL: THF, R1: 1,1-ethylphenylpropane, and R2:methyl, with traverse in the reply filed on 7/29/2026 is acknowledged. The Examiner believes this is an accurate representation of the structure: PNG media_image1.png 227 376 media_image1.png Greyscale The grounds for traversal are the Applicant argues that the claims are linked by a common inventive concept and share a common special technical feature. Further, the Applicant argues that the art cited by the Examiner fails to teach a hydrocarbyl group comprising a branched alkyl-aryl. The Examiner points to a secondary reference, included in the rejection below, that would be obvious to substitute such group. Therefore, unity is broken. Claims 18-25, 27-28, and 30-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected methods of using, there being no allowable generic or linking claim. No anticipatory art was found of the elected species, so the Examiner expanded the species pursuant to MPEP 803.02. The expanded species is described in the rejection. No anticipatory art was found, however is rejected in an obviousness-type 103 rejection below. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-6, 9, 13 are rejected under 35 U.S.C. 103 as being unpatentable over Coates, G. et al. (US9376413B1, pub. 2016; “Coates”) in further view Sookraj, S. et al. (US10590099B1, pub. March 2020; “Sookraj”). This rejection applies to the expanded specie. The Expanded specie substitutes instant R1 from the elected specie with 2,2-methylphenylethane, as recited in instant claim 3. The structure is seen below. PNG media_image2.png 224 371 media_image2.png Greyscale Coates teaches compound catalysts for use in carbonylation of epoxides for formation of lactones with an overlapping genus structure with instant Formula I. Coates teaches a structural example similar to the expanded specie. PNG media_image3.png 238 387 media_image3.png Greyscale Coates teaches an aromatic ring in the instant -R3 position, which meets the limitations of instant claim 2, where -R3 can be a hydrogen, methyl, C2-10 alkyl group or in combination form a six-membered ring that is optionally a substituted aromatic ring. Coates fails to teach a structural example where instant R1 is a branched alkyl-aryl, such as 2,2-methylphenylethane, and instant R2 is methyl. Sookraj teaches compound catalysts for use in carbonylation of epoxides for formation of lactones with an overlapping genus structure with instant Formula I. Sookraj teaches embodiments that would lead to the expanded specie, such as: PNG media_image4.png 115 226 media_image4.png Greyscale , where R4a is g: PNG media_image5.png 85 101 media_image5.png Greyscale (Page 18, Column 32), R3a is 2,2-methylphenylethane, as represented by the following example: PNG media_image6.png 163 135 media_image6.png Greyscale (Page 19, Column 34), and R1a is methyl, as represented by the following example: PNG media_image7.png 103 129 media_image7.png Greyscale (Page 20, Column 35). Sookraj fails to teach an explicit structural example of the combination of embodiments. However, it would be obvious to a person skilled in the art to extract the structure taught by Coates and substitute instant R1 is a branched alkyl-aryl, such as 2,2-methylphenylethane, and instant R2 is methyl, as taught by Sookraj. The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down inGraham. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR example rationale (B), it would have been prima facie obvious to extract the structure taught by Coates and substitute instant R1 is a branched alkyl-aryl, such as 2,2-methylphenylethane, and instant R2 is methyl, as taught by Sookraj. A person skilled in the art would be motivated to do so because both compounds are used as catalysts in the carbonylation of epoxides. Therefore, claims 1-6, 9, 13 would be obvious to a person skilled in the art at the time. Conclusion Claims 1-6, 9, 13 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLA MARIA BAUER whose telephone number is (703)756-1269. The examiner can normally be reached Monday-Friday 7:30-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clint Brooks can be reached at (571) 270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.M.B./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 05, 2024
Application Filed
Sep 10, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12770739
SERUM CYTOKINE PROFILE PREDICTIVE OF RESPONSE TO NON-SURGICAL LOW BACK PAIN TREATMENT
5y 10m to grant Granted Oct 20, 2026
Patent 12767639
METHOD FOR PRODUCING HALOVINYL IMIDAZOLE COMPOUND
2y 7m to grant Granted Oct 20, 2026
Patent 12760371
COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EFFICACY OF EGFR-TARGETED ANTI-CANCER AGENTS
4y 5m to grant Granted Oct 13, 2026
Patent 12758551
SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES
3y 11m to grant Granted Oct 13, 2026
Patent 12752011
BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND
3y 3m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+52.1%)
3y 8m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month